Oxaliplatin for the treatment of cisplatin-resistant cancer: a systematic review.
about
Taxane monotherapy for the treatment of platinum pre-treated epithelial ovarian cancerResistance to paclitaxel in a cisplatin-resistant ovarian cancer cell line is mediated by P-glycoproteinMR image-guided delivery of cisplatin-loaded brain-penetrating nanoparticles to invasive glioma with focused ultrasound.Anticancer activity of methyl-substituted oxaliplatin analogs.[A randomized clinical trial on the clinical efficacy and toxicities of single-agent paclitaxel liposome versus paclitaxel liposome plus oxaliplatin as first-line chemotherapy for advanced non-small cell lung cancer in elderly patients].Nanocarriers for delivery of platinum anticancer drugs.Cisplatin inhibits protein splicing, suggesting inteins as therapeutic targets in mycobacteria.Antimetabolite Treatment for Pancreatic Cancer.Acquired resistance to decitabine and cross-resistance to gemcitabine during the long-term treatment of human HCT116 colorectal cancer cells with decitabine.Platinum (IV)-fatty acid conjugates overcome inherently and acquired Cisplatin resistant cancer cell lines: an in-vitro study.Trial watch: Chemotherapy with immunogenic cell death inducersApplication of imaging mass spectrometry approaches to facilitate metal-based anticancer drug research.Chromatin folding and DNA replication inhibition mediated by a highly antitumor-active tetrazolato-bridged dinuclear platinum(II) complexTreatment of stage IIIb/IV non-small cell lung cancer with Pemetrexed plus Oxaliplatin after failure of Erlotinib as second-line treatmentNew-generation platinum agents for solid tumors.Anticancer activity of metal complexes: involvement of redox processes.Current and future management strategies for relapsed or progressive hepatoblastoma.Targeting and delivery of platinum-based anticancer drugs.Metallomics insights into the programmed cell death induced by metal-based anticancer compounds.Platinum-containing regimens for metastatic breast cancer.Induction of intrinsic and extrinsic apoptosis through oxidative stress in drug-resistant cancer by a newly synthesized Schiff base copper chelate.Rapamycin enhanced the antitumor efficacy of oxaliplatin in cisplatin-resistant ovarian cancer cells A2780cis both in vitro and in vivo.MiR-492 is functionally involved in Oxaliplatin resistance in colon cancer cells LS174T via its regulating the expression of CD147.Modulation of antitumor immunity contributes to the enhanced therapeutic efficacy of liposomal oxaliplatin in mouse model.A pH responsive complexation-based drug delivery system for oxaliplatinIrinotecan and DNA-PKcs inhibitors synergize in killing of colon cancer cells.Thermodynamics of translesion synthesis across a major DNA adduct of antitumor oxaliplatin: differential scanning calorimetric study.Structural study on the interactions of oxaliplatin and linear DNA.Kinetics and mechanistic investigation into the possible activation of imidazolium trans-[tetrachloridodimethylsulfoxideimidazoleruthenate(iii)], NAMI-A, by 2-mercaptoethane sulfonate
P2860
Q24235072-C42AF3D3-9570-4993-B5B2-4F7EB7C764C3Q28481246-4F269282-7690-4A53-A6C9-A6E5029DA98FQ30252977-321C7EAF-244F-41C4-BEAA-B1DF86AC9EAEQ30515979-080CEA24-A9C8-4B98-91E1-6A726EB9A523Q33399713-67931E06-FD0E-4163-83E3-8BDA8C650B49Q34338695-3D2C23D5-A7B3-4B69-9F93-7C3B93A9E15BQ34488965-B511F458-7951-430F-A0BD-9C02495518BAQ35826334-4A3FDB37-7E9B-44C7-9B15-B31C6BC2850DQ35870211-24E2E07D-2697-4594-9069-05680656824CQ35932794-4D183F08-6E35-4607-B1EC-F57047E10540Q36038456-E09198C2-5588-418C-890F-0C77E86D2D7CQ36268494-2307D733-7E19-4E8A-9385-2F4EE52CB8F7Q36814826-F4416425-6DB3-4839-9981-E51B8F0BC1E4Q36886148-9C2EEF17-7A86-4062-A705-D224017F6CC5Q37401326-8A1A9C99-5E67-43B1-ABD6-D29243021C14Q37833099-A012D27B-7D22-42E7-9410-BAB436B2D686Q38019027-15D5A85B-794E-48B0-B639-693150E72A04Q38050063-7CD57A3D-70C7-4B32-B20B-C7D639D80965Q38199383-56C27C3D-2604-4B00-9203-6E88E38EFAD5Q38712631-E32A4017-E950-4ACB-B421-F4723A9ED9FFQ38806350-5F03FD35-74DC-4175-A637-3D413450E622Q38874680-A54BBD2E-139E-4FAE-9969-7C09F6171C6CQ38888749-F39F656F-FF27-4C82-8359-78C5C03E128DQ41595487-84F74A1E-958A-40CE-BCD3-21F1141A3E4DQ41912667-76D01F86-EBDE-41DF-8C23-AF50769F52D3Q42759480-A42B52DB-1B2F-4E92-87E9-DC4025075E16Q50975254-FC0C3B9D-E0B7-4FEC-953C-503F4A42055DQ51258756-7D78186C-AB16-4DE2-B705-8326BF5CBCF9Q59205403-4FB286CD-19CA-421F-ADA9-A59B2A6A0E9D
P2860
Oxaliplatin for the treatment of cisplatin-resistant cancer: a systematic review.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Oxaliplatin for the treatment of cisplatin-resistant cancer: a systematic review.
@ast
Oxaliplatin for the treatment of cisplatin-resistant cancer: a systematic review.
@en
type
label
Oxaliplatin for the treatment of cisplatin-resistant cancer: a systematic review.
@ast
Oxaliplatin for the treatment of cisplatin-resistant cancer: a systematic review.
@en
prefLabel
Oxaliplatin for the treatment of cisplatin-resistant cancer: a systematic review.
@ast
Oxaliplatin for the treatment of cisplatin-resistant cancer: a systematic review.
@en
P2093
P1476
Oxaliplatin for the treatment of cisplatin-resistant cancer: a systematic review.
@en
P2093
Britta Stordal
Nick Pavlakis
Ross Davey
P304
P356
10.1016/J.CTRV.2007.01.009
P577
2007-03-23T00:00:00Z